Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
Terminated
- Conditions
- Carcinoma, Renal Cell
- Registration Number
- NCT05534789
- Lead Sponsor
- Pfizer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Terminated
- Sex
- All
- Target Recruitment
- 104
Inclusion Criteria
Inclusion Criteria:<br><br> - Participants diagnosed with locally advanced or metastatic renal cell carcinoma<br><br> - Participants with full medical information is available regarding all treatments<br> before, during and after 1st line<br><br>Exclusion Criteria:
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival
- Secondary Outcome Measures
Name Time Method Overall Survival (OS);Proportion of different drug regimen;Best response rate (RR);Duration of Response (DoR);Time to progression (TTP);Time to next treatment (TTNT);Number of participants with dose modifications;Number of participants with an interim/permanent discontinuation of one or all drugs of a therapy;Number of participants continuing therapy after dose modification;Number of participants continuing therapy after temporary/permanent discontinuation of single drugs